paroxetine has been researched along with amoxapine in 11 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (45.45) | 29.6817 |
2010's | 6 (54.55) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Ahman, M; Holmén, AG; Wan, H | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Dalvie, D; Loi, CM; Smith, DA | 1 |
Bellman, K; Knegtel, RM; Settimo, L | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Katsu, H; Nakayama, K; Ochiai, Y; Okino, S; Wakutsu, N | 1 |
Kato, S; Nishida, S; Nisijima, K; Shioda, K | 1 |
Fujimura, Y; Suhara, T | 1 |
Fujiyama, Y; Kato, M; Kinoshita, T; Nishida, K; Sakai, S; Sugimoto, T; Suwa, A; Tajika, A; Takekita, Y; Wakeno, M | 1 |
2 review(s) available for paroxetine and amoxapine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Biological pathophysiology of mood disorders special reference to the neurotransmitter receptors].
Topics: Amoxapine; Animals; Antidepressive Agents, Second-Generation; Brain; Humans; Ligands; Membrane Glycoproteins; Membrane Transport Proteins; Mood Disorders; Nerve Tissue Proteins; Paroxetine; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D1; Receptors, Serotonin, 5-HT2; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Trazodone | 2004 |
9 other study(ies) available for paroxetine and amoxapine
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
[Case of prolonged recovery from serotonin syndrome caused by paroxetine].
Topics: Amoxapine; Cytochrome P-450 CYP2D6; Depression; Diagnosis, Differential; Drug Interactions; Humans; Male; Middle Aged; Paroxetine; Polymorphism, Genetic; Serotonin Syndrome; Time Factors | 2003 |
Possible serotonin syndrome arising from an interaction between caffeine and serotonergic antidepressants.
Topics: Adult; Amoxapine; Caffeine; Central Nervous System Stimulants; Drug Interactions; Female; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome; Suicide, Attempted | 2004 |
Syndrome of inappropriate secretion of anti-diuretic hormone in an elderly depressive patient receiving paroxetine: a case report.
Topics: Amoxapine; Antidepressive Agents, Second-Generation; Depressive Disorder; Humans; Hyponatremia; Inappropriate ADH Syndrome; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sodium; Treatment Outcome | 2010 |